{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-039882","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.052175+00:00","generated_at":"2026-06-04T06:35:10.300979+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zura Bio reports FY2023 net loss $60.4M, cash $99.8M, appoints Robert Lisicki as CEO","bullets":["Net loss of $60.4M for FY2023 vs $25.7M in FY2022; R&D expenses $44.0M, G&A $18.6M.","Cash and equivalents of $99.8M as of Dec 31, 2023, expected to fund operations into 2026.","Founder and CEO Someit Sidhu steps down; President Robert Lisicki appointed CEO effective April 8, 2024.","Sidhu remains on board as non-independent director; Board expands to ten members.","Plans to initiate Phase 2 trial of tibulizumab (ZB-106) for systemic sclerosis in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-039882","json":"https://secwatch.observer/filing/0001104659-24-039882.json","markdown":"https://secwatch.observer/filing/0001104659-24-039882.md","text":"https://secwatch.observer/filing/0001104659-24-039882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/tm2410061d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:35:10.300979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23bf6d67227efcecd8c298a2e282c4a1f183e042","claim":"Zura Bio Ltd reported financial results for full year 2023.","evidence_excerpt":"Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"43420a9832","claim":"Someit Sidhu changed role as Chief Executive Officer at Zura Bio Ltd.","evidence_excerpt":"On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down as CEO"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7d84dca9ef","claim":"Robert Lisicki was appointed as Director at Zura Bio Ltd.","evidence_excerpt":"Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d945fc978a","claim":"Robert Lisicki changed role as Chief Executive Officer at Zura Bio Ltd.","evidence_excerpt":"Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}